Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA-4...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sci Transl Med
Hoofdauteurs: Hu-Lieskovan, Siwen, Mok, Stephen, Moreno, Blanca Homet, Tsoi, Jennifer, Faja, Lidia Robert, Goedert, Lucas, Pinheiro, Elaine M., Koya, Richard C., Graeber, Thomas, Comin-Anduix, Begoña, Ribas, Antoni
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4765379/
https://ncbi.nlm.nih.gov/pubmed/25787767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaa4691
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items